Credit Suisse’s Cyclerion Therapeutics CYCN Stock Holding History

Credit Suisse’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-802	Closed	-$42K	–	3983
2020 Q1	$42K	Buy	+802	New	+$57.2K	﹤0.01%	3915
2019 Q4	–	Sell	-691	Closed	-$167K	–	4184
2019 Q3	$167K	Buy	691 +132	+24%	+$28.5K	﹤0.01%	3905
2019 Q2	$128K	Buy	+559	New	+$158K	﹤0.01%	3926

Other funds holding CYCN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse's CYCN Position: Q2 2020 in Review

Credit Suisse sold out of Cyclerion Therapeutics (CYCN) in Q2 2020, closing a stake of 802 shares — an estimated $42K sold.

Credit Suisse first reported a position in CYCN in Q2 2019 and held it in 3 quarters. The position peaked at $167K in Q3 2019. 74 funds tracked by Wall St. Rank hold CYCN as of Q2 2020.

Credit Suisse reported no remaining Cyclerion Therapeutics position as of Q2 2020 after selling out during the quarter.
Credit Suisse sold 802 Cyclerion Therapeutics shares in Q2 2020, an estimated $42K.
Credit Suisse first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 3 quarters.
Credit Suisse's Cyclerion Therapeutics position peaked at $167K in Q3 2019.
74 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2020.

Based on Credit Suisse's 13F filing for Q2 2020, filed 12 Aug 2020.